KR20160030247A - 항체 제형 및 방법 - Google Patents

항체 제형 및 방법 Download PDF

Info

Publication number
KR20160030247A
KR20160030247A KR1020167003163A KR20167003163A KR20160030247A KR 20160030247 A KR20160030247 A KR 20160030247A KR 1020167003163 A KR1020167003163 A KR 1020167003163A KR 20167003163 A KR20167003163 A KR 20167003163A KR 20160030247 A KR20160030247 A KR 20160030247A
Authority
KR
South Korea
Prior art keywords
antibody
ser
formulation
concentration
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020167003163A
Other languages
English (en)
Korean (ko)
Inventor
패트릭 가리델
안드레아스 랑어
마이클 그런드먼
Original Assignee
프로테나 바이오사이언시즈 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51355583&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20160030247(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 프로테나 바이오사이언시즈 리미티드 filed Critical 프로테나 바이오사이언시즈 리미티드
Publication of KR20160030247A publication Critical patent/KR20160030247A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Analytical Chemistry (AREA)
  • Inorganic Chemistry (AREA)
KR1020167003163A 2013-07-04 2014-07-03 항체 제형 및 방법 Withdrawn KR20160030247A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361843011P 2013-07-04 2013-07-04
US61/843,011 2013-07-04
US201461979886P 2014-04-15 2014-04-15
US61/979,886 2014-04-15
PCT/IB2014/062806 WO2015001504A2 (en) 2013-07-04 2014-07-03 Antibody formulations and methods

Publications (1)

Publication Number Publication Date
KR20160030247A true KR20160030247A (ko) 2016-03-16

Family

ID=51355583

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020167003163A Withdrawn KR20160030247A (ko) 2013-07-04 2014-07-03 항체 제형 및 방법

Country Status (17)

Country Link
US (2) US10513555B2 (enExample)
EP (2) EP3524264A1 (enExample)
JP (3) JP6404338B2 (enExample)
KR (1) KR20160030247A (enExample)
CN (1) CN105492019B (enExample)
AU (1) AU2014285719A1 (enExample)
CA (1) CA2917097C (enExample)
CL (1) CL2015003801A1 (enExample)
CU (2) CU20170039A7 (enExample)
ES (1) ES2704440T3 (enExample)
IL (1) IL243425A0 (enExample)
MX (1) MX2016000201A (enExample)
PE (1) PE20160868A1 (enExample)
PH (1) PH12015502788A1 (enExample)
RU (1) RU2016103079A (enExample)
SG (1) SG11201510601TA (enExample)
WO (1) WO2015001504A2 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE037811T2 (hu) 2011-10-28 2018-09-28 Prothena Biosciences Ltd Alfa-szinukleint felismerõ humanizált antitestek
CN108517010A (zh) 2012-01-27 2018-09-11 普罗典娜生物科学有限公司 识别α-突触核蛋白的人源化抗体
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
CA2944402A1 (en) 2014-04-08 2015-10-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
MA42613A (fr) 2015-08-13 2018-06-20 Amgen Inc Filtration en profondeur chargée de protéines de liaison à un antigène
RU2731418C2 (ru) * 2015-09-28 2020-09-02 Сучжоу Санкадия Биофармасьютикалз Ко., Лтд. Стабильный фармацевтический препарат на основе антитела к pd-1 и его применение в медицине
CN105127166A (zh) * 2015-09-29 2015-12-09 中国华能集团清洁能源技术研究院有限公司 行走组件及具有其的光伏组件清洁装置
CN109415440B (zh) * 2016-06-27 2022-12-06 莫佛塞斯公司 抗-cd19抗体制剂
US10889635B2 (en) * 2016-11-15 2021-01-12 H. Lundbeck A/S Agents, uses and methods for the treatment of synucleinopathy
BR112018016717A2 (pt) 2016-12-16 2018-12-26 H Lundbeck As agentes, usos e métodos
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
BR112019016374A2 (pt) 2017-02-17 2020-04-07 Bristol-Myers Squibb Company anticorpos para alfa-sinucleína e usos dos mesmos
JP2021502955A (ja) * 2017-09-28 2021-02-04 プロセナ・バイオサイエンシズ・リミテッド シヌクレイン病の治療のための投与レジメン
US20190153102A1 (en) * 2017-09-28 2019-05-23 Prothena Biosciences Limited Dosing regimes for treatment of synucleinopathies
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
JP6831861B2 (ja) 2019-01-25 2021-02-17 株式会社Ｇｒｉｎ 歯科用測定器具、測定方法、及びアタッチメント器具
SG11202108627SA (en) 2019-02-18 2021-09-29 Lilly Co Eli Therapeutic antibody formulation
EP3786174A1 (en) * 2019-08-27 2021-03-03 Ichnos Sciences SA Methods for antibody purification
GB2587228B (en) * 2019-09-20 2021-10-27 Protein Ark Ltd Biological sample purification apparatus, use of the same, and systems comprising the same
MX2023000949A (es) 2020-07-23 2023-02-22 Othair Prothena Ltd Anticuerpos anti-beta-amiloide (abeta).
JP2023541048A (ja) 2020-09-10 2023-09-27 プロシーナ バイオサイエンシーズ リミテッド パーキンソン病の処置
CN114516914B (zh) * 2020-11-19 2023-04-28 东莞市朋志生物科技有限公司 抗n末端脑钠肽前体的抗体和检测n末端脑钠肽前体的试剂和试剂盒
CN117915952A (zh) 2021-09-16 2024-04-19 H.隆德贝克有限公司 用于治疗突触核蛋白病的组合物和方法

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
IE64738B1 (en) 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
WO1996024369A1 (en) 1995-02-06 1996-08-15 Genetics Institute, Inc. Formulations for il-12
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
MXPA01007845A (es) 1999-02-05 2004-06-22 Samsung Electronics Co Ltd Metodo para la recuperacion de la textura de imagenes y aparato para el mismo.
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
IL166244A0 (en) 2001-07-12 2006-01-15 Jefferson Foote Super humanized antibodies
JP4698950B2 (ja) 2002-04-09 2011-06-08 フラメル・テクノロジー アモキシシリンの改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤
AU2003299498A1 (en) 2002-05-13 2004-05-25 Alexion Pharmaceuticals, Inc. Humanized antibodies against the venezuelan equine encephalitis virus
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US9034337B2 (en) 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
JP4344325B2 (ja) 2002-11-29 2009-10-14 ベーリンガー インゲルハイム ファルマ ゲゼルシャフト ミット ベシュレンクテル ハフツング ウント コンパニー コマンディトゲゼルシャフト 新規なネオマイシンホスホトランスフェラーゼ遺伝子及び高生産組換え細胞の選抜方法
HRP20050934B1 (hr) 2003-04-04 2014-09-26 Genentech, Inc. Formulacije s visokom koncentracijom antitijela i proteina
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
US7674599B2 (en) 2003-11-08 2010-03-09 Elan Pharmaceuticals, Inc. Methods of using antibodies to detect alpha-synuclein in fluid samples
JP2007512846A (ja) 2003-12-04 2007-05-24 ゼンコー・インコーポレイテッド 増加した宿主ストリング含有量を有する変異体タンパク質の生成方法およびその組成物
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
CA2578400C (en) 2004-11-10 2014-01-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Use of flow-cytometric analysis to optimize cell banking strategies for cho cells
US20080300204A1 (en) 2005-07-19 2008-12-04 University Of Rochester Alpha-Synuclein Antibodies and Methods Related Thereto
AU2006329963B2 (en) * 2005-12-06 2011-06-09 Amgen Inc. Polishing steps used in multi-step protein purification processes
PL2468770T3 (pl) 2006-07-14 2018-07-31 Ac Immune S.A. Humanizowane przeciwciało przeciw amyloidowi beta
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
JP5558834B2 (ja) 2007-02-23 2014-07-23 ヤンセン アルツハイマー イミュノセラピー シヌクレイノパチーおよびアミロイド形成疾患（ａｍｙｌｏｉｄｏｇｅｎｉｃｄｉｓｅａｓｅ）の予防および処置
CN103396489A (zh) 2007-02-23 2013-11-20 默沙东公司 工程改造的抗IL-23p19抗体
US8147833B2 (en) * 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
SI2126093T1 (sl) 2007-03-02 2013-01-31 Boehringer Ingelheim Pharma Gmbh & Co. Kg Izboljšanje priprave proteinov
WO2008116103A2 (en) * 2007-03-22 2008-09-25 Imclone Llc Stable antibody formulations
RU2500686C2 (ru) 2007-03-22 2013-12-10 Дженентек, Инк. АПОПТОТИЧЕСКИЕ АНТИТЕЛА ПРОТИВ IgE
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
EP2225275A4 (en) * 2007-11-28 2013-04-03 Medimmune Llc PROTEIN FORMULATION
DK2234600T3 (da) 2007-12-21 2014-09-08 Hoffmann La Roche Antistofformulering
ES2544679T3 (es) 2007-12-28 2015-09-02 Prothena Biosciences Limited Tratamiento y profilaxis de la amiloidosis
JP5747414B2 (ja) 2008-04-29 2015-07-15 バイオアークティック ニューロサイエンス アーベー α−シヌクレイン関連疾患についての治療および診断方法における使用のための抗体およびワクチン
WO2009141239A1 (en) * 2008-05-20 2009-11-26 F. Hoffmann-La Roche Ag A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
US20120276019A1 (en) 2008-07-25 2012-11-01 Diamedica Inc. Tissue kallikrein for the treatment of parkinson's disease
EP3521309A1 (en) 2008-12-19 2019-08-07 Biogen International Neuroscience GmbH Human anti-alpha-synuclein antibodies
NZ713967A (en) 2009-07-28 2017-01-27 Shire Human Genetic Therapies Compositions and methods for treating gaucher disease
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
EP2519537A4 (en) 2009-12-29 2013-07-10 Reddys Lab Ltd Dr CLEANING PROTEINS
EP2366714A1 (en) 2010-03-03 2011-09-21 Dr. Rentschler Holding GmbH & Co. KG Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
EP2560994B1 (en) 2010-04-08 2016-10-12 JN Biosciences LLC Antibodies to cd122
TWI526161B (zh) 2010-06-10 2016-03-21 亞培公司 包含鈣ｈｍｂ及可溶性蛋白質之實質上透明營養液
ES2682078T3 (es) 2010-06-11 2018-09-18 Kyowa Hakko Kirin Co., Ltd. Anticuerpo anti-TIM-3
CA2805112A1 (en) 2010-07-15 2012-01-19 Synovex Corporation Humanized antibodies targeting the ec1 domain of cadherin-11 and related compositions and methods
JP6023715B2 (ja) * 2010-10-11 2016-11-09 アッヴィ・バハマズ・リミテッド タンパク質の精製方法
WO2012109280A2 (en) 2011-02-07 2012-08-16 Neotope Biosciences Limited Apoe immunotherapy
WO2012160536A1 (en) 2011-05-26 2012-11-29 Dr Reddy's Laboratories Limited Antibody purification
CN103764166B (zh) 2011-06-22 2017-10-24 通用医疗公司 蛋白质病的治疗
BR112013030472A2 (pt) * 2011-06-30 2019-09-24 Genentech Inc formulação farmacêutica, artigo de fabricação e método
PE20191242A1 (es) * 2011-10-25 2019-09-16 Prothena Biosciences Ltd Formulaciones de anticuerpo y metodos
HUE037811T2 (hu) 2011-10-28 2018-09-28 Prothena Biosciences Ltd Alfa-szinukleint felismerõ humanizált antitestek
LT3091029T (lt) 2011-10-31 2023-02-27 F. Hoffmann-La Roche Ag Anti-il13 antikūno kompozicijos
CN108517010A (zh) 2012-01-27 2018-09-11 普罗典娜生物科学有限公司 识别α-突触核蛋白的人源化抗体
US9216219B2 (en) * 2012-06-12 2015-12-22 Novartis Ag Anti-BAFFR antibody formulation
KR20190121874A (ko) 2012-08-29 2019-10-28 에프. 호프만-라 로슈 아게 혈액 뇌 장벽 셔틀
US8925815B2 (en) 2012-09-05 2015-01-06 Symbol Technologies, Inc. Checkout system for and method of preventing a customer-operated accessory reader facing a bagging area from imaging targets on products passed through a clerk-operated workstation to the bagging area
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
CA2944402A1 (en) 2014-04-08 2015-10-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
US10084674B2 (en) 2015-09-09 2018-09-25 International Business Machines Corporation Virtual desktop operation and data continuity preservation

Also Published As

Publication number Publication date
CU20170039A7 (es) 2017-06-05
SG11201510601TA (en) 2016-01-28
EP3016677A2 (en) 2016-05-11
CU20160001A7 (es) 2016-08-31
CL2015003801A1 (es) 2016-07-15
JP2021020941A (ja) 2021-02-18
JP6404338B2 (ja) 2018-10-10
RU2016103079A (ru) 2017-08-07
US10513555B2 (en) 2019-12-24
US20150079074A1 (en) 2015-03-19
CN105492019A (zh) 2016-04-13
PH12015502788A1 (en) 2016-03-21
CN105492019B (zh) 2020-02-11
WO2015001504A3 (en) 2015-08-06
IL243425A0 (en) 2016-03-31
CA2917097A1 (en) 2015-01-08
JP2016534052A (ja) 2016-11-04
ES2704440T3 (es) 2019-03-18
JP6854266B2 (ja) 2021-04-07
EP3524264A1 (en) 2019-08-14
AU2014285719A1 (en) 2016-01-21
WO2015001504A2 (en) 2015-01-08
EP3016677B1 (en) 2018-12-19
JP2019011339A (ja) 2019-01-24
HK1223544A1 (zh) 2017-08-04
US20200140534A1 (en) 2020-05-07
PE20160868A1 (es) 2016-09-24
CA2917097C (en) 2022-05-03
MX2016000201A (es) 2016-05-31

Similar Documents

Publication Publication Date Title
JP6854266B2 (ja) 抗体製剤および方法
JP7458327B2 (ja) 血液脳関門移動化合物及びその使用
US12384822B2 (en) TAM receptor-binding fusion molecule having non-inflammatory phagocytosis inducing activity
EP3725802A2 (en) Antibodies to alpha-synuclein and uses thereof
US20170274299A1 (en) Method for purification of monoclonal antibodies
RS63513B1 (sr) Anti-transtiretin antitela
WO2015075635A2 (en) Monitoring immunotherapy of lewy body disease from constipation symptoms
WO2021129775A1 (zh) 抗ctla-4单克隆抗体及其制备方法与应用
WO2023025217A1 (zh) 抗il4r抗体的药物组合物及其用途
CN118019759A (zh) 抗tdp-43的抗体及其使用方法
JP2022531979A (ja) 神経系における抗原結合タンパク質の発現
HK40005408A (en) Antibody purification method
EP4631975A1 (en) Fusion comprising anti-tau antibody and peptide and use thereof
HK1223544B (zh) 抗体制剂和方法
JP7691977B2 (ja) 抗ｔｉｒｃ７抗原結合タンパク質
CA3276286A1 (en) Fusion comprising anti-tau antibody and peptide and use thereof
HK40045548B (zh) 一种TGF-β受体融合蛋白药物组合物及其用途

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160203

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid